诺和诺德CEO强调强大研发实力有助拉动销售业绩

开始神话

13年12月4日讯  -尽管今年早些时候美国FDA否决了诺和诺德公司的新药Tresiba申请，并要求其进行进一步研究。这家丹麦制药巨头仍然对前路充满信心。公司CEO最近表示目前公司的研发实力有目共睹，并不会因为这些挫折而止步。同时他还指出公司未来销售业绩增长将主要依靠中国和其他国际市场。

详细英文报道：

Despite a major setback earlier this year when the FDA rejected Novo Nordisk's ($NVO) application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway. "I believe we have never had as strong a pipeline as we have right now," chief executive Lars Rebien S?rensen told investors today, according to a report in Reuters. Novo believes its future sales growth will come from China and other international markets.